What changed in HUTCHMED (China) Ltd's 2024 10-K compared to 2023?

Across the narrative sections we track, HUTCHMED (China) Ltd (HCM) added 0 paragraphs, removed 0, and edited 0 between the 2023 and 2024 10-K filings. The biggest movers are .

Where does this HCM 10-K diff come from?

The source filings are HUTCHMED (China) Ltd's official 2023 and 2024 Form 6-K annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

HUTCHMED (China) LtdHCM決算レポート

Nasdaq

HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.

What changed in HUTCHMED (China) Ltd's 6-K — 2023 vs 2024

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.

Other HCM 10-K year-over-year comparisons

HCM 10-K 2024 vs 2025
HCM 10-K 2022 vs 2023